Skip to main content
Mia Levy, MD, Oncology, Chicago, IL

MiaALevyMDPhD

Oncology • Chicago, IL

Breast Cancer

Director, Rush University Cancer Center

Request Appointment

Overview of Dr. Levy

Dr. Mia Levy is an oncologist in Chicago, IL and is affiliated with multiple hospitals in the area, including Rush University Medical Center and Rush-Copley Medical Center. She received her medical degree from Rush Medical College of Rush University Medical Center and has been in practice 14 years. Dr. Levy accepts several types of health insurance, listed below. She is one of 58 doctors at Rush University Medical Center and one of 11 doctors at Rush-Copley Medical Center who specialize in Oncology. She has more than 70 publications and over 500 citings.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2003 - 2005
  • Rush Medical College of Rush University Medical Center
    Rush Medical College of Rush University Medical CenterClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - Present
  • IL State Medical License
    IL State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2009 - 2021
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Clinical Application of Computational Methods in Precision Oncology  
    Mia A Levy, Christopher R Cogle, JAMA Oncology
  • Qualitative Study of System-Level Factors Related to Genomic Implementation  
    Geoffrey S Ginsburg, Joshua C Denny, Carol R Horowitz, Mia A Levy, Barbara A Bernhardt, Paul R Dexter, Stephen E Kimmel, Lori A Orlando, Nature

Authored Content

  • Clinical Application of Computational Methods in Precision OncologyMay 2020
  • Clinical Application of Computational Methods in Precision OncologyMay 2020

Press Mentions

  • U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (Inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
    U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (Inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA MutationOctober 11th, 2024
  • Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 26th, 2023
  • FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Exkivity
    FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for ExkivityMay 5th, 2023
  • Join now to see all

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    BCBS Tennessee Network 5
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Connecticare FlexPOS
    Coventry Carelink Health Plans PPO
    Great West PPO
    Health Net Arizona HMO
    Health Net Arizona PPO/POS
    Humana ChoiceCare Network PPO
    Humana/ChoiceCare+ Network PPO
    Multiplan PHCS PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Mia Levy, Dr. Mia Levy, MD, Dr. M Levy, Dr. Mia A Levy